• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.

作者信息

Contrera Kevin J, Gule-Monroe Maria K, Hu Mimi I, Cabanillas Maria E, Busaidy Naifa L, Dadu Ramona, Waguespack Steven G, Wang Jennifer R, Maniakas Anastasios, Lai Stephen Y, Diersing Julia, Kwon Michael, Grubbs Elizabeth G, Subbiah Vivek, Williams Michelle D, Zafereo Mark E

机构信息

Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Department of Neuroradiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Thyroid. 2023 Jan;33(1):129-132. doi: 10.1089/thy.2022.0506.

DOI:10.1089/thy.2022.0506
PMID:36503246
Abstract
摘要

相似文献

1
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.用于甲状腺髓样癌的新辅助选择性RET抑制剂：病例系列
Thyroid. 2023 Jan;33(1):129-132. doi: 10.1089/thy.2022.0506.
2
Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.甲状腺髓样癌中耐药克隆的出现可能无法通过后续的挽救性转染期间高度选择性重排抑制剂治疗得到挽救。
Thyroid. 2021 Feb;31(2):332-333. doi: 10.1089/thy.2020.0449. Epub 2020 Aug 4.
3
Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.酪氨酸激酶抑制剂用于治疗甲状腺髓样癌
Recent Results Cancer Res. 2015;204:227-49. doi: 10.1007/978-3-319-22542-5_11.
4
Neoadjuvant selpercatinib for advanced medullary thyroid cancer.新辅助塞浦替尼治疗晚期甲状腺髓样癌。
Head Neck. 2021 Jan;43(1):E7-E12. doi: 10.1002/hed.26527. Epub 2020 Nov 9.
5
Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report.髓样甲状腺癌脉络膜转移灶对高选择性RET抑制剂塞尔帕替尼有显著反应：一例报告
Ann Oncol. 2021 Nov;32(11):1447-1449. doi: 10.1016/j.annonc.2021.08.1987. Epub 2021 Aug 20.
6
Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.基于椭圆屈碱衍生物的用于治疗甲状腺髓样癌的有效 RET 转录抑制剂的展示。
Int J Oncol. 2017 Jul;51(1):145-157. doi: 10.3892/ijo.2017.3994. Epub 2017 May 11.
7
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.挑战临床无反应性甲状腺髓样癌：新型RET抑制剂的发现及药理活性
Eur J Med Chem. 2018 Apr 25;150:491-505. doi: 10.1016/j.ejmech.2018.02.080. Epub 2018 Mar 2.
8
Transcriptional targeting of oncogene addiction in medullary thyroid cancer.转录靶向治疗甲状腺髓样癌中的癌基因成瘾。
JCI Insight. 2018 Aug 23;3(16). doi: 10.1172/jci.insight.122225.
9
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of , , and .ONC201 通过转录抑制,, 和 表现出针对甲状腺髓样癌的强大抗癌活性。
Mol Cancer Ther. 2021 Apr;20(4):665-675. doi: 10.1158/1535-7163.MCT-20-0386. Epub 2021 Feb 3.
10
Selpercatinib.塞尔帕替尼
Am J Health Syst Pharm. 2020 Oct 30;77(22):1818-1821. doi: 10.1093/ajhp/zxaa279.

引用本文的文献

1
Neoadjuvant Chemotherapy With Selpercatinib for Locally Advanced Fusion-Positive Papillary Thyroid Carcinoma: A Case Report.塞尔帕替尼用于局部晚期融合阳性乳头状甲状腺癌的新辅助化疗：一例报告
Case Rep Endocrinol. 2025 Jun 3;2025:6676471. doi: 10.1155/crie/6676471. eCollection 2025.
2
Systemic therapies for medullary thyroid carcinoma: state of the art.甲状腺髓样癌的全身治疗：最新进展
Ther Adv Endocrinol Metab. 2025 May 11;16:20420188251336091. doi: 10.1177/20420188251336091. eCollection 2025.
3
Landmark Studies in Differentiated Thyroid Cancer.
分化型甲状腺癌的标志性研究。
Ann Surg Oncol. 2025 May 9. doi: 10.1245/s10434-025-17419-1.
4
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.多激酶和高选择性激酶抑制剂在甲状腺癌患者新辅助治疗中的应用
Explor Target Antitumor Ther. 2025 Feb 13;6:1002291. doi: 10.37349/etat.2025.1002291. eCollection 2025.
5
The potential role of neoadjuvant treatment in thyroid cancers in the era of kinase inhibitors: a narrative review.激酶抑制剂时代新辅助治疗在甲状腺癌中的潜在作用：一篇叙述性综述。
Endocrine. 2025 Feb 4. doi: 10.1007/s12020-025-04182-2.
6
Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma.加拿大多学科关于高危及放射性碘难治性甲状腺癌多模式管理的共识
Front Oncol. 2024 Nov 4;14:1437360. doi: 10.3389/fonc.2024.1437360. eCollection 2024.
7
Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma.局部晚期甲状腺癌的新辅助治疗
J Clin Med. 2024 Sep 27;13(19):5769. doi: 10.3390/jcm13195769.
8
Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma.塞尔帕替尼在放射性碘治疗儿童甲状腺滤泡状癌之前。
J Pediatr Endocrinol Metab. 2024 Sep 3;37(11):1009-1014. doi: 10.1515/jpem-2024-0281. Print 2024 Nov 26.
9
European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management.欧洲内分泌外科学会（ESES）关于晚期甲状腺癌的共识声明：定义与管理
Br J Surg. 2024 Aug 2;111(8). doi: 10.1093/bjs/znae199.
10
Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial.阿帕替尼作为局部晚期分化型甲状腺癌新辅助治疗的疗效与安全性：一项2期试验
J Endocr Soc. 2024 Jul 12;8(9):bvae132. doi: 10.1210/jendso/bvae132. eCollection 2024 Jul 26.